Superbug Fight Escalates: BioVersys Secures Major Funding for Novel Antibiotic Trial
November 12, 2025, 9:37 pm
BioVersys receives CHF 14 million from Wellcome for a pivotal BV100 Phase 2b clinical trial. This study tackles carbapenem-resistant Acinetobacter baumannii (CRAB), a "critical" WHO priority pathogen. BV100 offers a novel intravenous rifabutin formulation, uniquely targeting Gram-negative RNA-polymerase. The ADVANCE-ID network will conduct the expanded trial in Southeast Asia, boosting patient numbers and treatment arms. This global effort aims to generate vital data for upcoming BV100 Phase 3 regulatory submissions across the US, Europe, and China, combating life-threatening hospital-acquired infections and strengthening the worldwide fight against antibiotic resistance.
The battle against superbugs intensifies. Antibiotic resistance poses a grave global health crisis. Urgent solutions are necessary. A new clinical trial offers significant hope. BioVersys, a pioneering biopharmaceutical company, recently secured substantial funding. Wellcome awarded CHF 14 million (SGD 22 million) to advance its BV100 program. This funding targets a critical pathogen: Carbapenem-resistant *Acinetobacter baumannii* (CRAB).
CRAB is a "critical" priority pathogen. The World Health Organization (WHO) classified it as such in 2017. It causes severe, often fatal, hospital-acquired infections. These include ventilator-associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP), and bloodstream infections (BSI). Treatment options are severely limited. New antibiotics are desperately needed. BV100 aims to fill this void.
BV100 is a novel intravenous formulation. It uses rifabutin, an established antibiotic. Its mechanism of action is groundbreaking. BV100 actively takes rifabutin into Gram-negative bacteria. This allows it to target the RNA-polymerase enzyme. This approach is unprecedented for Gram-negative pathogens at human-suitable doses. It represents a significant scientific leap. BV100 holds promise against the toughest drug-resistant strains.
The funded study is a Phase 2b clinical trial. It will run in parallel to an upcoming Phase 3 study. This dual-track approach accelerates drug development. The Phase 2b trial aims to generate additional clinical data. It will collect real-world evidence. This is crucial for future BV100 new drug applications. The study also allows comparison with newer approved drugs. This provides vital context for BV100's efficacy.
The ADVANCE-ID network conducts the trial. ADVANCE-ID stands for ADVANcing Clinical Evidence in Infectious Diseases. Its hub is at the Saw Swee Hock School of Public Health, National University of Singapore. This network boasts extensive experience. It has conducted clinical research on over 10,000 patients. Over 3,000 patients had VABP/HABP. Over 7,000 patients suffered from BSI. CRAB was a prevalent cause of these life-threatening infections across Asia. Wellcome initially supported ADVANCE-ID's setup in 2022. This new funding further strengthens the network. It enables its first sponsor-driven clinical trial.
The Phase 2b study is open-label and randomized. It will take place across several countries in Southeast Asia. This region experiences very high levels of drug-resistant infections. This setting provides invaluable data. It reflects the real-world challenge of superbug proliferation. BioVersys collaborates closely with ADVANCE-ID. This partnership is vital.
The study design has expanded. It now includes three treatment arms. Initially, it planned for two. The expanded design includes two BV100 arms. One combines BV100 with Ceftazidime/avibactam. The other combines BV100 with Cefiderocol. A third arm provides Best Available Therapy. This comparative approach yields robust data.
Patient enrollment has also increased. Part A of the study focuses on patients with VABP/HABP and BSI suffering from CRAB. The number of evaluable patients in Part A rose from 60 to 90. Part B addresses additional patient populations. It will enroll 10 patients with CRAB ventriculitis and meningitis. This comprehensive patient group enhances study outcomes.
The first patient dosing is anticipated in early 2026. Interim data is expected in the second half of 2026. This timeline highlights the urgency of the mission. The data generated will be critical. It will contribute directly to the BV100 Phase 3 program. This program targets regulatory submissions. Key markets include the US, Europe, and China. Securing approvals in these regions is paramount for global access.
BV100 represents a promising weapon. It targets an urgent medical need. The collaboration between BioVersys and ADVANCE-ID, supported by Wellcome, is a powerful alliance. It accelerates the development of a novel antibiotic. This global effort fights drug-resistant infections. It protects patients worldwide from deadly superbugs. The stakes are incredibly high. Scientific innovation offers our best defense. This trial marks a pivotal step forward.
The battle against superbugs intensifies. Antibiotic resistance poses a grave global health crisis. Urgent solutions are necessary. A new clinical trial offers significant hope. BioVersys, a pioneering biopharmaceutical company, recently secured substantial funding. Wellcome awarded CHF 14 million (SGD 22 million) to advance its BV100 program. This funding targets a critical pathogen: Carbapenem-resistant *Acinetobacter baumannii* (CRAB).
CRAB is a "critical" priority pathogen. The World Health Organization (WHO) classified it as such in 2017. It causes severe, often fatal, hospital-acquired infections. These include ventilator-associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP), and bloodstream infections (BSI). Treatment options are severely limited. New antibiotics are desperately needed. BV100 aims to fill this void.
BV100 is a novel intravenous formulation. It uses rifabutin, an established antibiotic. Its mechanism of action is groundbreaking. BV100 actively takes rifabutin into Gram-negative bacteria. This allows it to target the RNA-polymerase enzyme. This approach is unprecedented for Gram-negative pathogens at human-suitable doses. It represents a significant scientific leap. BV100 holds promise against the toughest drug-resistant strains.
The funded study is a Phase 2b clinical trial. It will run in parallel to an upcoming Phase 3 study. This dual-track approach accelerates drug development. The Phase 2b trial aims to generate additional clinical data. It will collect real-world evidence. This is crucial for future BV100 new drug applications. The study also allows comparison with newer approved drugs. This provides vital context for BV100's efficacy.
The ADVANCE-ID network conducts the trial. ADVANCE-ID stands for ADVANcing Clinical Evidence in Infectious Diseases. Its hub is at the Saw Swee Hock School of Public Health, National University of Singapore. This network boasts extensive experience. It has conducted clinical research on over 10,000 patients. Over 3,000 patients had VABP/HABP. Over 7,000 patients suffered from BSI. CRAB was a prevalent cause of these life-threatening infections across Asia. Wellcome initially supported ADVANCE-ID's setup in 2022. This new funding further strengthens the network. It enables its first sponsor-driven clinical trial.
The Phase 2b study is open-label and randomized. It will take place across several countries in Southeast Asia. This region experiences very high levels of drug-resistant infections. This setting provides invaluable data. It reflects the real-world challenge of superbug proliferation. BioVersys collaborates closely with ADVANCE-ID. This partnership is vital.
The study design has expanded. It now includes three treatment arms. Initially, it planned for two. The expanded design includes two BV100 arms. One combines BV100 with Ceftazidime/avibactam. The other combines BV100 with Cefiderocol. A third arm provides Best Available Therapy. This comparative approach yields robust data.
Patient enrollment has also increased. Part A of the study focuses on patients with VABP/HABP and BSI suffering from CRAB. The number of evaluable patients in Part A rose from 60 to 90. Part B addresses additional patient populations. It will enroll 10 patients with CRAB ventriculitis and meningitis. This comprehensive patient group enhances study outcomes.
The first patient dosing is anticipated in early 2026. Interim data is expected in the second half of 2026. This timeline highlights the urgency of the mission. The data generated will be critical. It will contribute directly to the BV100 Phase 3 program. This program targets regulatory submissions. Key markets include the US, Europe, and China. Securing approvals in these regions is paramount for global access.
BV100 represents a promising weapon. It targets an urgent medical need. The collaboration between BioVersys and ADVANCE-ID, supported by Wellcome, is a powerful alliance. It accelerates the development of a novel antibiotic. This global effort fights drug-resistant infections. It protects patients worldwide from deadly superbugs. The stakes are incredibly high. Scientific innovation offers our best defense. This trial marks a pivotal step forward.